Comparative evaluation of atenolol and metoprolol on cardiovascular complications associated with streptozotocin-induced diabetic rats

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 8, 2007, Pages 831-836

  Bhadada, Shraddha V ^a,b   Goyal, Ramesh K ^a  

^a L M COLLEGE OF PHARMACY   (India)

^b NIRMA UNIVERSITY   (India)

Author keywords

Atenolol; Cardiac complications; Diabetes mellitus; Metoprolol

Indexed keywords

ATENOLOL; METOPROLOL TARTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERTENSION; INSULIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATENOLOL; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOMEGALY; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; HEART RATE; INSULIN; METOPROLOL; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TRIGLYCERIDES;

EID: 36348937410     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y07-069     Document Type: Article

References (40)

1. Arauz-Pacheco, C, Parrott, M.A., and Raskin, P. 2002. The treatment of hypertension in adult patients with diabetes. Diabetes Care, 25: 134-147. doi:10.2337/diacare.25.1.134.
2. Bangaru, R.A., Lakkad, N.B., and Goyal, R.K. 1996. Effects of chronic atenolol treatment on diabetes induced cardiac depression and other complications. Indian J. Pharmacol. 23: 33-34.
3. Basat, O., Ucak, S., Seber, S., Oztekin, E., and Altuntas, Y. 2006. After myocardial infarction Carvedilol improves insulin resistance compared to metoprolol. Clin. Res. Cardiol. 95: 99-104. doi:10.1007/s00392-006-0336- 4.
4. Bell, D.S. 2004. Advantages of a third generation beta blocker in patients with diabetes mellitus. Am. J. Cardiol. 93 (9A): 49B-52B. doi:10.1016/j.amjcard.2004.01.026.
5. Carlson, L.A., and Botinger, L.E. 1972. Ischemic Heart Disease in relation to fasting values of plasma triglycerides and cholesterol. Lancet, 1: 805-808.
6. Cavaliere, T.A., Taylor, D.G., Kerwin, L.J., and Antonaccia, M.J. 1980. Cardiovascular effects of alloxan diabetes in normotensive and spontaneously hypertensive rats. Pharmacology, 20: 211-223.
7. Cleophas, T.C., and Van Der Meulen, J. 1999. Beta-blockers: ancillary properties important after all? East. J. Med. 4: 1-5.
8. Cruickshank, J.M. 2000. Beta blockers continue to surprise us. Eur. Heart J. 21: 354-364. doi:10.1053/euhj.1999.1717.
9. Day, J.L., Metcalfe, J., and Simpson, C.N. 1982. Adrenergic mechanisms in control of plasma lipid concentration. Br. Med. J. (Clin. Res. Ed.), 284: 1145-1148.
10. Dharmalingam, M., Deshpande, N., and Vidyasagar, S. 2004. Triglyceride levels and its correlation with carotid-intima-media thickness. Int. J. Diabetes Dev. Countries, 4: 19-22.
11. Gilbert, E.M., Abraham, W.T., Olsen, S., Hattler, B., White, M., Mealy, P., et al. 1996. Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation, 94: 2817-2825.
12. Goyal, R.K. 1999. Hyperinsulinemia and insulin resistance in hypertension: Differential effects of antihypertensive agents. Clin. Exp. Hypertens. 21: 167-179.
13. Goyal, R.K., and McNeill, J.H. 1985. Effects of chronic STZ-induced diabetes on the cardiac responses to milrinone. Can. J. Physiol. Pharmacol. 63: 1620-1623.
14. Grossman, E., Shemesh, J., Shamiss, A., Thaler, M., Carroll, J., and Rosenthal, T. 1992. Left ventricular mass in diabetes-hypertension. Arch. Intern. Med. 152: 1001-4. doi:10.1001/archinte.152.5.1001.
15. Hausdorff, W.P., Caron, M.G., and Lefkowitz, R.J. 1990. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 4: 2881-2889.
16. Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H., and Berglund, G. 2001. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima media thickness: Main results from the Beta Blocker Cholesterol Lowering Asymptomatic Plaque study (BCAPS). Circulation, 103: 1721-1726.
17. Heinemann, L., Heise, T., Ampudia, J., Sawicki, P., Sindelka, G., Brunner, G., and Starke, A.A.R. 1995. Four week administration of an ACE inhibitor and a cardioselective β-blocker in healthy volunteers: no influence on insulin sensitivity. Eur. J. Clin. Invest. 25: 595-600.
18. Hjalmarson, A. 1988. International beta blocker review in acute and post myocardial infarction. Am. J. Cardiol. 61: 26B-29B. doi:10.1016/0002- 9149(88)91352-5.
19. Hjalmarson, A., Herlitz, J., Holmberg, S., Rydén, L., Swedberg, K., Vedin, A., et al. 1983. The Göteborg Metoprolol Trial. Effect on mortality and morbidity in acute myocardial infarction. Circulation, 67: 126-132.
20. 1 blockers: Safe effective treatment for hypertension. Postgrad. Med. 89: 89-112.
21. Kaplan, J.R., and Manuck, S.B. 1999. Status, stress, and atherosclerosis: the role of environment and individual behaviour. Ann. N. Y. Acad. Sci. 896: 145-147. doi:10.1111/j.1749-6632.1999.tb08112.x.
22. Kendall, M.J. 1997. Clinical relevance of pharmacokinetic differences between beta blockers. Am. J. Cardiol. 80 (9B): 15J-19J. doi:10.1016/S0002-9149(97)00833-3.
23. Laakso, M., Edelman, S.V., Breditel, G., and Baron, A.D. 1996. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J. Clin. Invest. 85: 1844-1852.
24. Majmudar, S.R. 1999. β-blockers for the treatment of hypertension in patients with diabetes: exploring the contradiction myth. Cardiovasc. Drugs Ther. 5: 435-439.
25. Prakash, A., and Markham, A. 2000. Metoprolol: a review of its use in chronic heart failure. Drugs, 60: 647-678. doi:10.2165/00003495- 200060030-00011.
26. Rapaport, E. 1997. Pharmacological therapy for acute myocardial infarction. Postgrad. Med. 102: 143-145.
27. Satia, M.C., Shukla, M.L., Gandhi, T.P., and Goyal, R.K. 1997. Prevalence of hypertension and comparative evaluation of four antihypertensive monotherapy in Indian NIDDM hypertensive patients. Indian J. Hypertens. 2: 17-27.
28. Savarese, J.J., and Berkowitz, B.A. 1979. Beta adrenergic receptors decrease in diabetic rat hearts. Life Sci. 25: 2075-2078. doi:10.1016/0024-3205(79)90200-5.
29. Sirtori, C.R., Johnson, B., Vaccarino, V., Montanari, G., Cremoncini, M., Gianfranceschi, G., et al. 1989. Lipid effects of celiprolol, a new cardioselective beta blocker versus propranolol. Clin. Pharmacol. Ther. 45: 617-626.
30. Soriano, J.B., Ferro, A., and Wilhelmi, E. 1997. Increased survival with beta-blockers: importance of ancillary properties. Prog. Cardiovasc. Dis. 93: 445-456.
31. Sowers, J.R., Epstein, M., and Frohlich, E.D. 2001. Diabetes, Hypertension, and Cardiovascular Disease: An Update. Hypertension, 37: 1053-1068.
32. The MIAMI Trial Research Group. 1985. Metoprolol in Acute Myocardial Infarction (MIAMI). A randomized placebo controlled international trial. Eur. Heart J. 6: 199-226.
33. Tomlinson, K.C., Gardiner, S.M., Herdes, R.A., and Binnet, T. 1992. Functional consequences of streptozotocin induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol. Rev. 44: 103-150.
34. Umrani, D.N., and Goyal, R.K. 2002. Beneficial effects of fenoldopam treatment on renal functions in streptozotocin induced diabetic rats. Clin. Exp. Hypertens. 24: 207-219. doi:10.1081/CEH-120003201.
35. Weidmann, P., Uehlinger, D.E., and Gerber, A. 1985. Antihypertensive treatment and serum lipoproteins. J. Hypertens. 3: 295-306.
36. Wiklund, O., Hulthe, J., Wikstrand, J., Schmidt, C., Olofsson, S.O., and Bondjers, G. 2002. Effect of controlled release/extended release metoprolol on carotid intima media thickness inpatients with hypercholesterolaemia: a 3 year randomized study. Stroke, 33: 572-577. doi:10.1161/hs0202.102332.
37. Wikstrand, J., Warnold, I., Olsson, G., Tuomilehto, J., Elmfeldt, D., and Berglund, G. 1988. Primary prevention with metoprolol in patients with hypertension. Mortality results form the MAPHY Study. JAMA, 259: 1976-1982. doi:10.1001/jama.259.13.1976.
38. Wikstrand, J., Warnold, I., Tuomilehto, J., Olsson, G., Barber, H.J., Eliasson, K., et al. 1991. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension, 17: 579-588.
39. Wikstrand, J., Berglund, G., Hedblad, B., and Hulthe, J. 2003. Antiatherosclerotic effects of beta blockers. Am. J. Cardiol. 91: 25H-29H. doi:10.1016/S0002-9149(03)00431-4.
40. Wilhelmsen, L., Berglund, C., Elmfeldt, D., Fitzimons, T., Holzgreve, H., and Hosie, J. 1987. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J. Hypertens. 5: 561-572. doi:10.1097/00004872-198710000-00009.